Pharmacological data of the atypical neuroleptic compound melperone (Buronil).
Based on the non-cataleptic properties, the weak affinity for D2 receptors and the inability to induce DA receptor supersensitivity after both acute and repeated administration, melperone may be characterized as an atypical neuroleptic drug. This indicates a weak effect of melperone on striatal DA neurotransmission. On the other hand melperone is potent in blocking amphetamine induced locomotion, exploratory behaviour, L-Dopa induced jumping and aggression suggesting a limbic mode of action. The effect on limbic DA neurotransmission together with an antiadrenergic and 5-HT modulating action may explain the antipsychotic effect and the low incidence of extrapyramidal side effects observed during treatment with melperone.
Christensson
E G
EG
CNS-Research, Pharmacia-LEO Therapeutics AB, Malmö, Sweden.
D000818:Animals; D014150:Antipsychotic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D001143:Arousal / Q000187:drug effects*; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000187:drug effects*; D002090:Butyrophenones / Q000493:pharmacokinetics / Q000494:pharmacology*; D051379:Mice; D009043:Motor Activity / Q000187:drug effects*; D051381:Rats; D017981:Receptors, Neurotransmitter / Q000187:drug effects
D014150:Antipsychotic Agents; D002090:Butyrophenones; D017981:Receptors, Neurotransmitter; C008522:metylperon